Adrenocorticotropic hormone analog use for podocytopathies

Edward J. Filippone, Shirley J. Dopson, Denise Rivers, Rebeca D. Monk, Suneel M. Udani, Golriz Jafari, Solomon C. Huang, Arafat Melhem, Bassim Assioun, Paul G. Schmitz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Adrenocorticotropic hormone is being increasingly studied for treatment of various glomerulopathies, most notably membranous nephropathy. Less data are available regarding its use in idiopathic nephrotic syndrome (INS) secondary to minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). We report here our experience with H.P. Acthar® Gel (repository corticotropin injection) as first-line or subsequent therapy in patients with INS. Methods: Data were taken from three patients with MCD and ten patients with FSGS from around the US, who were treated with Acthar Gel as initial or subsequent therapy. Treatment was solely at the discretion of the primary nephrologist without a specific protocol. A complete response (CR) was defined as final urine protein-to-creatinine ratio,500 mg/g and a partial response (PR) as 50% decrease without rise of serum creatinine. Side effects and tolerability were noted. Results: All three patients with MCD received Acthar Gel as second-line or later immunosuppressive (IS) therapy and all responded (one CR and two PRs). Two of the ten patients with FSGS received Acthar Gel as first-line IS therapy, while the other eight had failed multiple agents. Four of the ten patients with FSGS had responses, including two CRs and two PRs. The three patients with MCD tolerated therapy well without side effects. Five patients with FSGS tolerated therapy well, while five had various steroid-like side effects, resulting in therapy discontinuation in two patients. Conclusion: Acthar Gel is a viable alternative IS agent for treatment of INS in patients intolerant or resistant to conventional therapy. More data are needed to better define its appropriate place.

Original languageEnglish (US)
Pages (from-to)125-133
Number of pages9
JournalInternational Medical Case Reports Journal
Volume9
DOIs
StatePublished - Jun 28 2016

Fingerprint

Adrenocorticotropic Hormone
Focal Segmental Glomerulosclerosis
Lipoid Nephrosis
Gels
Immunosuppressive Agents
Therapeutics
Creatinine
Membranous Glomerulonephritis
Steroids
Urine
Injections

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Filippone, E. J., Dopson, S. J., Rivers, D., Monk, R. D., Udani, S. M., Jafari, G., ... Schmitz, P. G. (2016). Adrenocorticotropic hormone analog use for podocytopathies. International Medical Case Reports Journal, 9, 125-133. https://doi.org/10.2147/IMCRJ.S104899

Adrenocorticotropic hormone analog use for podocytopathies. / Filippone, Edward J.; Dopson, Shirley J.; Rivers, Denise; Monk, Rebeca D.; Udani, Suneel M.; Jafari, Golriz; Huang, Solomon C.; Melhem, Arafat; Assioun, Bassim; Schmitz, Paul G.

In: International Medical Case Reports Journal, Vol. 9, 28.06.2016, p. 125-133.

Research output: Contribution to journalArticle

Filippone, EJ, Dopson, SJ, Rivers, D, Monk, RD, Udani, SM, Jafari, G, Huang, SC, Melhem, A, Assioun, B & Schmitz, PG 2016, 'Adrenocorticotropic hormone analog use for podocytopathies', International Medical Case Reports Journal, vol. 9, pp. 125-133. https://doi.org/10.2147/IMCRJ.S104899
Filippone, Edward J. ; Dopson, Shirley J. ; Rivers, Denise ; Monk, Rebeca D. ; Udani, Suneel M. ; Jafari, Golriz ; Huang, Solomon C. ; Melhem, Arafat ; Assioun, Bassim ; Schmitz, Paul G. / Adrenocorticotropic hormone analog use for podocytopathies. In: International Medical Case Reports Journal. 2016 ; Vol. 9. pp. 125-133.
@article{71f6ac890dd8463da2ad73a186df835e,
title = "Adrenocorticotropic hormone analog use for podocytopathies",
abstract = "Background: Adrenocorticotropic hormone is being increasingly studied for treatment of various glomerulopathies, most notably membranous nephropathy. Less data are available regarding its use in idiopathic nephrotic syndrome (INS) secondary to minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). We report here our experience with H.P. Acthar{\circledR} Gel (repository corticotropin injection) as first-line or subsequent therapy in patients with INS. Methods: Data were taken from three patients with MCD and ten patients with FSGS from around the US, who were treated with Acthar Gel as initial or subsequent therapy. Treatment was solely at the discretion of the primary nephrologist without a specific protocol. A complete response (CR) was defined as final urine protein-to-creatinine ratio,500 mg/g and a partial response (PR) as 50{\%} decrease without rise of serum creatinine. Side effects and tolerability were noted. Results: All three patients with MCD received Acthar Gel as second-line or later immunosuppressive (IS) therapy and all responded (one CR and two PRs). Two of the ten patients with FSGS received Acthar Gel as first-line IS therapy, while the other eight had failed multiple agents. Four of the ten patients with FSGS had responses, including two CRs and two PRs. The three patients with MCD tolerated therapy well without side effects. Five patients with FSGS tolerated therapy well, while five had various steroid-like side effects, resulting in therapy discontinuation in two patients. Conclusion: Acthar Gel is a viable alternative IS agent for treatment of INS in patients intolerant or resistant to conventional therapy. More data are needed to better define its appropriate place.",
author = "Filippone, {Edward J.} and Dopson, {Shirley J.} and Denise Rivers and Monk, {Rebeca D.} and Udani, {Suneel M.} and Golriz Jafari and Huang, {Solomon C.} and Arafat Melhem and Bassim Assioun and Schmitz, {Paul G.}",
year = "2016",
month = "6",
day = "28",
doi = "10.2147/IMCRJ.S104899",
language = "English (US)",
volume = "9",
pages = "125--133",
journal = "International Medical Case Reports Journal",
issn = "1179-142X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Adrenocorticotropic hormone analog use for podocytopathies

AU - Filippone, Edward J.

AU - Dopson, Shirley J.

AU - Rivers, Denise

AU - Monk, Rebeca D.

AU - Udani, Suneel M.

AU - Jafari, Golriz

AU - Huang, Solomon C.

AU - Melhem, Arafat

AU - Assioun, Bassim

AU - Schmitz, Paul G.

PY - 2016/6/28

Y1 - 2016/6/28

N2 - Background: Adrenocorticotropic hormone is being increasingly studied for treatment of various glomerulopathies, most notably membranous nephropathy. Less data are available regarding its use in idiopathic nephrotic syndrome (INS) secondary to minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). We report here our experience with H.P. Acthar® Gel (repository corticotropin injection) as first-line or subsequent therapy in patients with INS. Methods: Data were taken from three patients with MCD and ten patients with FSGS from around the US, who were treated with Acthar Gel as initial or subsequent therapy. Treatment was solely at the discretion of the primary nephrologist without a specific protocol. A complete response (CR) was defined as final urine protein-to-creatinine ratio,500 mg/g and a partial response (PR) as 50% decrease without rise of serum creatinine. Side effects and tolerability were noted. Results: All three patients with MCD received Acthar Gel as second-line or later immunosuppressive (IS) therapy and all responded (one CR and two PRs). Two of the ten patients with FSGS received Acthar Gel as first-line IS therapy, while the other eight had failed multiple agents. Four of the ten patients with FSGS had responses, including two CRs and two PRs. The three patients with MCD tolerated therapy well without side effects. Five patients with FSGS tolerated therapy well, while five had various steroid-like side effects, resulting in therapy discontinuation in two patients. Conclusion: Acthar Gel is a viable alternative IS agent for treatment of INS in patients intolerant or resistant to conventional therapy. More data are needed to better define its appropriate place.

AB - Background: Adrenocorticotropic hormone is being increasingly studied for treatment of various glomerulopathies, most notably membranous nephropathy. Less data are available regarding its use in idiopathic nephrotic syndrome (INS) secondary to minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). We report here our experience with H.P. Acthar® Gel (repository corticotropin injection) as first-line or subsequent therapy in patients with INS. Methods: Data were taken from three patients with MCD and ten patients with FSGS from around the US, who were treated with Acthar Gel as initial or subsequent therapy. Treatment was solely at the discretion of the primary nephrologist without a specific protocol. A complete response (CR) was defined as final urine protein-to-creatinine ratio,500 mg/g and a partial response (PR) as 50% decrease without rise of serum creatinine. Side effects and tolerability were noted. Results: All three patients with MCD received Acthar Gel as second-line or later immunosuppressive (IS) therapy and all responded (one CR and two PRs). Two of the ten patients with FSGS received Acthar Gel as first-line IS therapy, while the other eight had failed multiple agents. Four of the ten patients with FSGS had responses, including two CRs and two PRs. The three patients with MCD tolerated therapy well without side effects. Five patients with FSGS tolerated therapy well, while five had various steroid-like side effects, resulting in therapy discontinuation in two patients. Conclusion: Acthar Gel is a viable alternative IS agent for treatment of INS in patients intolerant or resistant to conventional therapy. More data are needed to better define its appropriate place.

UR - http://www.scopus.com/inward/record.url?scp=84983329150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983329150&partnerID=8YFLogxK

U2 - 10.2147/IMCRJ.S104899

DO - 10.2147/IMCRJ.S104899

M3 - Article

VL - 9

SP - 125

EP - 133

JO - International Medical Case Reports Journal

JF - International Medical Case Reports Journal

SN - 1179-142X

ER -